Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En maskert, placebokontrollert studie for å vurdere Iptacopan i aldersrelatert makuladegenerasjon

26. oktober 2026 oppdatert av: Novartis Pharmaceuticals

En randomisert, deltaker og etterforsker maskert, placebokontrollert, multisenter, bevis-av-konsept-studie for å vurdere sikkerheten og effekten av LNP023 (Iptacopan) hos pasienter med tidlig og middels aldersrelatert makuladegenerasjon

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.

Studieoversikt

Detaljert beskrivelse

This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).

Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:

  • Iptacopan (LNP023) oral capsules
  • Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.

Studietype

Intervensjonell

Registrering (Faktiske)

168

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Fullerton, California, Forente stater, 92835
        • Retina Consultants of Orange County
      • Huntington Beach, California, Forente stater, 92647
        • Salehi Retina Institute
      • Rancho Cordova, California, Forente stater, 95670
        • Martel Eye Medical Group
      • Sacramento, California, Forente stater, 95841
        • Retinal Consultants Medical Group Inc
      • Santa Barbara, California, Forente stater, 93103
        • California Retina Consultants
    • Colorado
      • Durango, Colorado, Forente stater, 81303
        • Southwest Retina Research Center
    • Florida
      • Deerfield Beach, Florida, Forente stater, 33064
        • Advanced Research LLC
      • Delray Beach, Florida, Forente stater, 33484
        • Retina Center Of South Florida
      • St. Petersburg, Florida, Forente stater, 33711
        • Retina Vitreous Associates of Florida
    • Indiana
      • Carmel, Indiana, Forente stater, 46032
        • Midwest Eye Institute
    • Louisiana
      • Metairie, Louisiana, Forente stater, 70001
        • Retina Associates New Orleans
    • Maryland
      • Baltimore, Maryland, Forente stater, 21209
        • Retina Care Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Opthamalic Consultants of Boston
    • New Jersey
      • Bloomfield, New Jersey, Forente stater, 07003
        • Envision Ocular LLC
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Duke Eye Center
    • Oregon
      • Portland, Oregon, Forente stater, 97210
        • Retina Northwest PC
    • Tennessee
      • Germantown, Tennessee, Forente stater, 38138
        • Charles Retina Institute
    • Texas
      • Austin, Texas, Forente stater, 78793
        • Austin Research Center for Retina
      • Bellaire, Texas, Forente stater, 77401
        • Retina Consultants TX Rsrch Ctr
      • Dallas, Texas, Forente stater, 75231
        • Retina Foundation
      • Fort Worth, Texas, Forente stater, 76104
        • Texas Retina Associates
      • Houston, Texas, Forente stater, 77030
        • Retina Consultants of Houston PA
      • Shanghai, Kina, 200080
        • Novartis Investigative Site
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150001
        • Novartis Investigative Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300020
        • Novartis Investigative Site
      • Arecibo, Puerto Rico, 00612
        • Emanuelli Research and Development Center LLC
      • London, Storbritannia, SE5 9RS
        • Novartis Investigative Site
      • Southampton, Storbritannia, SO16 6YD
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female participants ≥ 50 years of age
  • Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
  • Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
  • Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
  • Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
  • If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.

Exclusion Criteria:

  • History or current diagnosis of ECG abnormalities indicating significant safety risk, such as clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
  • History of familial long QT syndrome or known family history of Torsades de Pointes
  • History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
  • History of end stage kidney disease requiring dialysis or renal transplant
  • History of malignancy of any organ system
  • History of solid organ or bone marrow transplantation
  • History of recurrent meningitis or history of meningococcal infections despite vaccination
  • History of immunodeficiency diseases, including a positive Human Immunodeficiency Virus test result at Screening
  • Active Hepatitis B (HBV) or Hepatitis C (HCV) infection
  • History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
  • Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
  • Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Iptacopan (LNP023)

Iptacopan (LNP023) oral use capsules

oral capsules

Placebo komparator: Placebo

Placebo matched to study drug, oral use capsules

oral capsules

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging
Tidsramme: Baseline/Day 1 through Month 24

OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines

Baseline/Day 1 through Month 24

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The incidence of ocular and non-ocular adverse events (AEs)
Tidsramme: Baseline/Day 1 through Month 24

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study.

Baseline/Day 1 through Month 24
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24

Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts.

Baseline/Day 1 through Month 24
Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24

ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts.

Baseline/Day 1 through Month 24
Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24

Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read.

Baseline/Day 1 through Month 24
Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24

MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes.

Baseline/Day 1 through Month 24
Pharmacokinetics - concentrations of LNP023 related to trough samples
Tidsramme: Baseline/Day 1 through Month 24

Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method.

Baseline/Day 1 through Month 24
Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24

MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes.

Baseline/Day 1 through Month 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. februar 2022

Primær fullføring (Faktiske)

19. august 2026

Studiet fullført (Faktiske)

30. september 2026

Datoer for studieregistrering

Først innsendt

28. januar 2022

Først innsendt som oppfylte QC-kriteriene

28. januar 2022

Først lagt ut (Faktiske)

9. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

27. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere